GeneOne Life Science Inc Total Assets
GeneOne Life Science Inc total assets. Based on the latest financial reports, GeneOne Life Science Inc (011000) holds total assets worth ₩131.29 Billion KRW (≈ $88.97 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 011000 market cap for the company's overall valuation and market capitalisation.
Total Assets of GeneOne Life Science Inc (2009–2025)
Total assets of GeneOne Life Science Inc from 2009 to 2025. This chart illustrates how GeneOne Life Science Inc's total assets have evolved over time, based on quarterly financial data. See 011000 live share price for real-time trading data and today's change.
GeneOne Life Science Inc - Asset Composition Analysis
GeneOne Life Science Inc Total Assets Breakdown (December 2025)
GeneOne Life Science Inc total assets breakdown as of December 2025. GeneOne Life Science Inc's total assets of ₩131.29 Billion consist of 16.3% current assets and 83.7% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 1.1% |
| Accounts Receivable | ₩1.74 Billion | 1.5% |
| Inventory | ₩13.42 Billion | 11.3% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩208.41 Million | 0.2% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how GeneOne Life Science Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of GeneOne Life Science Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GeneOne Life Science Inc's current assets represent 16.3% of total assets in 2025, an increase from 0.0% in 2009.
- Cash Position: Cash and equivalents constituted 1.1% of total assets in 2025, down from 6.9% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 28.0% in 2009.
- Asset Diversification: The largest asset category is inventory at 11.3% of total assets.
GeneOne Life Science Inc Competitors by Total Assets
Key competitors of GeneOne Life Science Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
GeneOne Life Science Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.46 | 0.63 | 2.48 |
| Quick Ratio | 0.21 | 0.25 | 2.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-29.25 Billion | ₩-16.26 Billion | ₩49.84 Billion |
GeneOne Life Science Inc - Advanced Valuation Insights
This section examines the relationship between GeneOne Life Science Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.95 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -21.2% |
| Total Assets | ₩119.21 Billion |
| Market Capitalization | $32.81 Million USD |
Valuation Analysis
Below Book Valuation: The market values GeneOne Life Science Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: GeneOne Life Science Inc's assets decreased by 21.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for GeneOne Life Science Inc (2009–2025)
The table below shows the annual total assets of GeneOne Life Science Inc from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩119.21 Billion ≈ $80.78 Million |
-21.23% |
| 2024-12-31 | ₩151.33 Billion ≈ $102.56 Million |
+0.22% |
| 2023-12-31 | ₩151.01 Billion ≈ $102.34 Million |
-32.24% |
| 2022-12-31 | ₩222.87 Billion ≈ $151.03 Million |
-10.67% |
| 2021-12-31 | ₩249.50 Billion ≈ $169.08 Million |
+82.69% |
| 2020-12-31 | ₩136.57 Billion ≈ $92.55 Million |
+166.99% |
| 2019-12-31 | ₩51.15 Billion ≈ $34.67 Million |
+3.77% |
| 2018-12-31 | ₩49.30 Billion ≈ $33.41 Million |
+8.02% |
| 2017-12-31 | ₩45.63 Billion ≈ $30.93 Million |
-30.50% |
| 2016-12-31 | ₩65.66 Billion ≈ $44.50 Million |
+37.68% |
| 2015-12-31 | ₩47.69 Billion ≈ $32.32 Million |
+16.99% |
| 2014-12-31 | ₩40.77 Billion ≈ $27.63 Million |
+28.11% |
| 2013-12-31 | ₩31.82 Billion ≈ $21.56 Million |
-20.37% |
| 2012-12-31 | ₩39.96 Billion ≈ $27.08 Million |
-1.24% |
| 2011-12-31 | ₩40.46 Billion ≈ $27.42 Million |
+1.02% |
| 2010-12-31 | ₩40.05 Billion ≈ $27.14 Million |
-32.16% |
| 2009-12-31 | ₩59.04 Billion ≈ $40.01 Million |
-- |
About GeneOne Life Science Inc
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, whic… Read more